In vivo SELEX for Identification of Brain-penetrating Aptamers

The physiological barriers of the brain impair drug delivery for treatment of many neurological disorders. One delivery approach that has not been investigated for their ability to penetrate the brain is RNA-based aptamers. These molecules can impart delivery to peripheral tissues and circulating immune cells, where they act as ligand mimics or can be modified to carry payloads. We developed a library of aptamers and an in vivo evolution protocol to determine whether specific aptamers could be identified that would home to the brain after injection into the peripheral vasculature. Unlike biopanning with recombinant bacteriophage libraries, we found that the aptamer library employed here required more than 15 rounds of in vivo selection for convergence to specific sequences. The aptamer species identified through this approach bound to brain capillary endothelia and penetrated into the parenchyma. The methods described may find general utility for targeting various payloads to the brain.

[1]  P. Lockman,et al.  The blood-brain barrier choline transporter as a brain drug delivery vector. , 2003, Life sciences.

[2]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[3]  M. Kolonin,et al.  An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. , 2011, Cell stem cell.

[4]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[5]  Charles M. Rice,et al.  A genetically humanized mouse model for hepatitis C virus infection , 2011, Nature.

[6]  W. Pardridge.  Blood-brain barrier biology and methodology. , 1999, Journal of neurovirology.

[7]  François Guillemin,et al.  Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. , 2012, Current drug metabolism.

[8]  Todd M. Allen,et al.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. , 2011, The Journal of clinical investigation.

[9]  K. Thompson,et al.  Pharmacokinetics and Biodistribution of Novel Aptamer Compositions , 2004, Pharmaceutical Research.

[10]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[11]  W. Pardridge.  Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[12]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[13]  D. Curiel,et al.  Directing adenovirus across the blood–brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model , 2007, Gene Therapy.

[14]  Michael Famulok,et al.  Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures , 2010, Nature Protocols.

[15]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[16]  M. De Block,et al.  RNA-RNA in situ hybridization using digoxigenin-labeled probes: the use of high-molecular-weight polyvinyl alcohol in the alkaline phosphatase indoxyl-nitroblue tetrazolium reaction. , 1993, Analytical biochemistry.

[17]  William A Banks,et al.  Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease , 2008, BMC Neuroscience.

[18]  A. Dalpiaz,et al.  Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach , 2008, Molecules.

[19]  R. Buhmann,et al.  Aptamers—basic research, drug development, and clinical applications , 2005, Applied Microbiology and Biotechnology.

[20]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[21]  P. Klotman,et al.  Identification and characterization of a cell membrane nucleic acid channel. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Starzyk,et al.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  John J. Rossi,et al.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells , 2009, Nucleic acids research.

[24]  Amy C Yan,et al.  A General RNA Motif for Cellular Transfection , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  W. Duan,et al.  RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule , 2011, Cancer science.

[26]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[27]  X. Breakefield,et al.  Viral vectors for gene delivery to the nervous system , 2003, Nature Reviews Neuroscience.

[28]  B. Sullenger,et al.  In vivo selection of tumor-targeting RNA motifs , 2009, Nature chemical biology.

[29]  B. Hyman,et al.  Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging , 2011, Proceedings of the National Academy of Sciences.

[30]  I. Zuhorn,et al.  In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice. , 2012, Molecular pharmaceutics.

[31]  M. Weinand,et al.  Human Immunodeficiency Virus Type 1 Enters Brain Microvascular Endothelia by Macropinocytosis Dependent on Lipid Rafts and the Mitogen-Activated Protein Kinase Signaling Pathway , 2002, Journal of Virology.

[32]  A. Ellington,et al.  Directed evolution of gold nanoparticle delivery to cells. , 2010, Chemical communications.

[33]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[34]  R. Johnston,et al.  The Role of the Blood-Brain Barrier during Venezuelan Equine Encephalitis Virus Infection , 2011, Journal of Virology.

[35]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[36]  W. Pardridge,et al.  Biopharmaceutical drug targeting to the brain , 2010, Journal of drug targeting.

[37]  Dong-Ki Lee,et al.  Nucleic acid aptamers targeting cell-surface proteins. , 2011, Methods.

[38]  Lihong Liu,et al.  Modern methods for delivery of drugs across the blood-brain barrier. , 2012, Advanced drug delivery reviews.

[39]  M. Tomi,et al.  Gene expression profiles of ATP-binding cassette transporter A and C subfamilies in mouse retinal vascular endothelial cells. , 2008, Microvascular research.

[40]  P. Bates,et al.  A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. , 2010, Cancer research.